Idiopathic intracranial hypertension secondary to fluoroquinolone therapy: French pharmacovigilance data review.
A HureauxM BermejoP M SuretM BonnetY N'GuyenM HentzienZ DjeradaB AzzouzFirouzé Bani-SadrPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2023)
We investigate spontaneous reports of IIH related to fluoroquinolones recorded in the French national pharmacovigilance database in order to detect a possible pharmacovigilance signal. The association between IIH risk and fluoroquinolone exposure was assessed using a case/non-case study. Between 1985 and July 2023, 17 reports of IIH after fluoroquinolone exposure were recorded. No specific fluoroquinolone was predominant. IIH led to death in one case and blindness in one case. The Reporting Odds Ratio was 2.58 (95% confidence interval 1.59-4.19). We highlight statistically significant disproportionality, which constitutes a pharmacovigilance signal. IIH risk after fluoroquinolone exposure is a class effect.